Mileutis, an Israel-based biopharmaceutical company, announced on Tuesday that it has added Bret Kossman and Ori Inbar as new executives to its board of directors.

Presently, Kossman is the managing director and head of Research and Analysis for Bank of America Merrill Lynch's Global Credit and Special Situations Group. He has served as the head of Japan Corporate Principal Investments and head of Asia Distressed Trading for Merrill Lynch, where he headed investments in private and public equity, mezzanine, and distressed debt. He has served as an investment banker at Salomon Smith Barney/Citigroup in New York and Tokyo where he worked on various capital raising and M&A transactions.

Inbar has more than 30 years of experience in the dairy industry and is presently an independent entrepreneur, investor, and consultant in agricultural technologies. He has more than 18 years of experience at Inbar where he has served as senior executive in SCR Dairy (currently owned by Merck & Co.). During his 18 years at SCR, he has held the position of senior executive and vice-president for Marketing, Sales, and Product Management.